Supporting KIF18A’s therapeutic promise in genomically unstable cancers like triple-negative breast cancer and high-grade serous ovarian cancers, multiple KIF18A inhibitors have been developed and were recently reviewed by Chen and colleagues [147]. This evidence concerns the gene KIF18A and ovarian serous adenocarcinoma.